iCo Therapeutics Begins Trading on OTCQX®

Dec 20, 2013, 07:00 ET from OTC Markets Group Inc.

NEW YORK, Dec. 20, 2013 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that iCo Therapeutics, Inc. (OTCQX: ICOTF; TSX-V: ICO), a Vancouver-based reprofiling company with exclusive worldwide rights to two drug candidates – iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases, has been approved to trade on OTCQX®, the best marketplace with qualified companies.

(Logo: http://photos.prnewswire.com/prnh/20110118/MM31963LOGO)

iCo Therapeutics begins trading today on OTCQX International, a segment of the OTCQX marketplace reserved for high-quality non-U.S. companies that are listed on a qualified international exchange and provide their home country disclosure to U.S. investors.  U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

"We are pleased iCo Therapeutics has chosen to trade on the OTCQX marketplace," said R. Cromwell Coulson, President and CEO of OTC Markets Group Inc.  "iCo is advancing new treatments for life-threatening ophthalmic diseases.  We are proud to welcome the company to our OTCQX marketplace where U.S. investors will find timely access to iCo's news and disclosure and transparent trading information to ease in analyzing, valuing and trading its securities." 

"We look forward to increasing awareness of iCo Therapeutics' ongoing clinical developments and progress in the United States, the single most important biotechnology investor market globally, by trading on the OTCQX marketplace," said Andrew Rae, President and CEO of iCo Therapeutics.

Troutman Sanders LLP serves as iCo Therapeutics' Principal American Liaison ("PAL") on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. federal securities laws.

iCo Therapeutics has exclusive worldwide rights to two drug candidates – iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases.  iCo-007 is in Phase 2 clinical studies for DME.  With Phase 2 clinical history, iCo-008 is targeted for the treatment of vernal or atopic keratoconjunctivitis and wet age-related macular degeneration.

iCo Therapeutics will trade in the U.S. on OTCQX under the symbol "ICOTF."

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into marketplaces to better inform investors of opportunities and risks – OTCQX®, The Best Marketplace with Qualified Companies; OTCQB®, The Venture Stage Marketplace with U.S. Reporting Companies; and OTC Pink®, The Open Marketplace with Variable Reporting Companies. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.

OTC Link® ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

Subscribe to the OTC Markets RSS Feed

SOURCE OTC Markets Group Inc.